A Randomized Controlled Trial of the Effects of Transcendental Meditation on Quality of Life in Older Breast Cancer Patients

Integrative Cancer Therapies

Volumn 8, Issue 3, 2009, Pages 228-234

  Nidich, Sanford I ^a   Fields, Jeremy Z ^b   Rainforth, Maxwell V ^a   Pomerantz, Rhoda ^c   Cella, David ^d   Kristeller, Jean ^e   Salerno, John W ^a   Schneider, Robert H ^a  

^a Management Research Institute   (United States)

^b Center for Healthy Aging   (United States)

^c Resurrection Health Care   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e INDIANA STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Oncology; Survival; Transcendental Meditation

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELDERLY CARE; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SINGLE BLIND PROCEDURE; SOCIAL LIFE; TRANSCENDENTAL MEDITATION; WELLBEING;

AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MEDITATION; MIDDLE AGED; NEOPLASM STAGING; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRES; SAMPLE SIZE; SINGLE-BLIND METHOD; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 70350026352     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735409343000     Document Type: Article

References (77)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun MJ Cancer statistics, 2003. CA Cancer J Clin. 2003 ; 53: 5-26.
2. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society ; 2007.
3. Moadel AB, Shah C., Wylie-Rosett J., et al. Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. J Clin Oncol. 2007 ; 25: 4387-4395.
4. Ganz PA, Guadagnoli E., Landrum MB, Lash TL, Rakowski W., Silliman RA Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol. 2003 ; 21: 4027-4033.
5. Ganz PA, Coscarelli A., Fred C., Kahn B., Polinsky ML, Petersen L. Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat. 1996 ; 38: 183-199.
6. Gellert GA, Maxwell R., Siegal B. Survival of breast cancer patients receiving adjunctive psychosocial support therapy: a 10-year follow-up study. J Clin Oncol. 1993 ; 11: 66-99.
7. Antoni MH, Lutgendorf SK, Cole SW, et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer. 2006 ; 6: 240-248.
8. Andersen BL, Kiecolt-Glaser JK, Glaser R. A bio-behavioral model of cancer stress and disease course. Am Psychol. 1994 ; 49: 389-404.
9. Bovbjerg DH Psychoneuroimmunology: a critical analysis of the implications for oncology in the 21st century. In: Lewis CE, Oĝ€™Sullivan C, Barraclough J, eds. Psychoimmunology of Cancer: Mind and Body in the Fight for Survival? Oxford, UK: Oxford University Press ; 1994: 417-426.
10. Bovbjerg, DH, Conditioning, cancer, and immune regulation. Brain Behav Immun. 2003 ; 17 Suppl 1: S58-61.
11. Spiegel D., Kato P. Psychological influences on cancer incidence and progression. Harv Rev Psychiatry. 1996 ; 4: 10-26.
12. Spiegel D. Psychological aspects of breast cancer treatment. Semin Oncol. 1997 ; 24 (suppl 1). S1-36 - S31-47.
13. Stewart DE, Cheung AM, Duff S., et al. Attributions of cause and recurrence in long-term breast cancer survivors. Psychooncology. 2001 ; 10: 179-183.
14. Kissane DW, Bloch S., Smith GC, et al. Cognitive-existential group psychotherapy for women with primary breast cancer: a randomised controlled trial. Psychooncology. 2003 ; 12: 532-546.
15. Derogatis LR, Morrow GR, Fetting J., et al. The prevalence of psychiatric disorders among cancer patients. JAMA. 1983 ; 249: 751-757.
16. Hughes JE, Royle GT, Buchanan R., Taylor I. Depression and social stress among patients with benign breast disease. Br J Surg. 1986 ; 73: 997-999.
17. Irving D., Brown B., Crooks D., Roberts J., Browne G. Psychosocial adjustment in women with breast cancer. Cancer. 1991 ; 67: 1097-1117.
18. Goldberg JA, Scott RN, Davidson PM Psychological morbidity in the first year after breast surgery. Eur J Surg Oncol. 1992 ; 18: 327-331.
19. Maraste R., Brandt L., Olsson H., Ryde-Brandt B. Anxiety and depression in breast cancer patients at start of adjuvant radiotherapy: relations to age and type of surgery. Acta Oncol. 1992 ; 31: 641-643.
20. Mermelstein HT, Lesko L. Depression in patients with cancer. Psychooncology. 1992 ; 1: 199-215.
21. Omne-Ponten M., Holmberg L., Sjoden PO Psychosocial adjustment among women with breast cancer stages I and II: six-year follow-up of consecutive patients. J Clin Oncol. 1994 ; 12: 1778-1782.
22. Ferrell BR, Grant M., Funk B., Garcia N., Otis-Green S., Schaffner ML Quality of life in breast cancer. Cancer Pract. 1996 ; 4: 331-340.
23. Levy D., Thom TJ Death rates from coronary disease: progress and a puzzling paradox. N Engl J Med. 1998 ; 339: 915-917.
24. Hughes J. Emotional reactions to the diagnosis and treatment of early breast cancer. J Psychosom Res. 1982 ; 26: 277-283.
25. Luebbert K., Dahme B., Hasenbring M. The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review. Psychooncology. 2001 ; 10: 490-502.
26. Devine C., Westlake G. The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies. Oncol Nurs Forum. 1995 ; 22: 1369-1381.
27. Fawzy FI, Fawzy NW, Arndt LA, Pasnau RO Critical review of psychosocial interventions in cancer care. Arch Gen Psych. 1995 ; 52: 100-113.
28. Meyer TJ, Mark MM Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments. Health Psychol. 1995 ; 14: 101-108.
29. Sheard T., Maguire P. The effects of psychological interventions on anxiety and depression in oncology. Psychooncology. 1996 ; 5 (suppl): 19.
30. Iacovino V., Reesor K. Literature on interventions to address cancer patientsĝ€™ psychosocial needs: what does it tell us ? J Psychosoc Oncol. 1997 ; 15: 47-71.
31. Spiegel D., Kraemer H., Bloom JR, Gottheil E. Effects of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989 ; 2: 888-891.
32. Reavley N., Pallant JF, Sali A. Evaluation of the effects of a psychosocial intervention on mood, coping and quality of life in cancer patients. Integr Cancer Ther. 2009 ; 8: 47-55.
33. Carlson L., Ursuliak Z., Goodey E., Angen M., Speca M. The effects of a mindfulness meditation based stress reduction program on mood and symptoms of stress in cancer outpatients: 6 month follow-up. Support Care Cancer. 2001 ; 9: 112-123.
34. Eppley K., Abrams AI, Shear J. Differential effects of relaxation techniques on trait anxiety: a meta-analysis. J Clin Psychol. 1989 ; 45: 957-974.
35. Alexander CN, Rainforth MY, Gelderloos P. Transcendental Meditation, self-actualization and psychological health: a conceptual overview and statistical meta-analysis. J Soc Behav Pers. 1991 ; 6: 189-247.
36. MacLean C., Walton K., Wenneberg S., et al. Effects of the Transcendental Meditation program on adaptive mechanisms: changes in hormone levels and responses to stress after 4 months of practice. Psychoneuroendocrinology. 1997 ; 22: 277-295.
37. Schneider RH, Alexander CN, Staggers F., et al. Long-term effects of stress reduction on mortality in persons >" xbd="2181" xhg="2161" ybd="1713" yhg="1687"/>55 years of age with systemic hypertension. Am J Cardiol. 2005 ; 95: 1060-1064.
38. Orme-Johnson DW Medical care utilization and the Transcendental Meditation program. Psychosom Med. 1987 ; 49: 493-507.
39. Orme-Johnson DW, Herron RE An innovative approach to reducing medical care utilization and expenditures. Am J Manag Care. 1997 ; 3: 135-144.
40. Nidich R., Nidich S., Schneider R. The Transcendental Meditation program and quality of life in breast cancer patients: a feasibility study. J Psychosom Res. 2003 ; 55: 153.
41. Maharishi Mahesh Yogi. The Science of Being and the Art of Living. New York, NY: New American Library Inc ; 1963.
42. Maharishi Mahesh Yogi. Maharishi Forum of Natural Law and National Law for Doctors. India: Age of Enlightenment Publications ; 1995.
43. Roth R. Maharishi Mahesh Yogiĝ€™s Transcendental Meditation. Washington, DC: Primus ; 2002.
44. Jevning R., Wallace RK, Biedebach M. The physiology of meditation: a review. A wakeful hypometabolic integrated response. Neurosci Biobehav Rev. 1992 ; 16: 415-424.
45. Wallace RK Physiological effects of Transcendental Meditation. Science. 1970 ; 167: 1751-1754.
46. Dillbeck MC, Orme-Johnson DW Physiological differences between Transcendental Meditation and rest. Am Psychol. 1987 ; 42: 879-881.
47. Subrahmanyam S., Potkodi D. Neurohumoral correlates of Transcendental Meditation. J Biomed. 1980 ; 1: 73-88.
48. Infante JR, Torres-Avisbal M., Pinel P., et al. Catecholamine levels in practitioners of the Transcendental Meditation technique. Physiol Behav. 2001 ; 72: 141-146.
49. Travis F., Wallace RK Autonomic and EEG patterns during eyes-closed rest and Transcendental Meditation (TM) practice: the basis for a neural model of TM practice. Conscious Cogn. 1999 ; 8: 302-318.
50. Cella DF, Tulsky DS, Gray G., et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol. 1993 ; 11: 570-579.
51. Brady M., Cella DF, Mo F., et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of life instrument. J Clin Oncol. 1997 ; 15: 974-986. (Pubitemid 27106280)
52. Cella DF, Tulsky DS, Gray G., et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol. 1993 ; 11: 570-579.
53. Brady M., Peterman AH, Fitchett G., Mo M., Cella DF A case for including spirituality in quality of life measurement in oncology. Psychooncology. 1999 ; 8: 417-428.
54. Ware J., Sherbourne C. The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. Med Care. 1992 ; 30: 473-483.
55. Little RJA, Rubin DB Statistical Analysis With Missing Data. New York, NY: Wiley ; 1987.
56. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol. 1996 ; 27: 957-1047.
57. Stefanek M., McDonald P. Brain, behavior and immunity in cancer. In: Miller S, Bowen D, Croyle R, Rowland J, eds. Handbook of Behavioral Science and Cancer. Washington, DC: American Psychological Association 2008: 499-516.
58. Reiche E., Nunes S., Morimoto H. Stress, depression, the immune system and cancer. Lancet Oncol. 2004 ; 5: 617-625.
59. Spiegel D., Geise-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry. 2003 ; 54: 269-282.
60. Price MA, Tennant CC, Smith RC, et al. The role of psychosocial factors in the development of breast carcinoma: Part I. The cancer prone personality. Cancer. 2001 ; 91: 679-685.
61. Lillberg K., Verkasalo PK, Kaprio J., Teppo L., Helenius H., Koskenvuo M. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemiol. 2003 ; 157: 415-423.
62. Glaser R., Kiecolt-Glaser JK Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005 ; 5: 243-251.
63. Chrousos GP, Gold PW The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis. JAMA. 1992 ; 267: 1244-1252.
64. Charmandari E., Tsigos C., Chrousos G. Endocrinology of the stress response. Annu Rev Physiol. 2005 ; 67: 259-284.
65. McEwen BS Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmacology. 2000 ; 22: 108-124.
66. Sood AK, Bhatty R., Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006 ; 12: 369-375.
67. Badino GR, Novelli A., Girardi C., Di Carlo F. Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res. 1996 ; 33: 255-260.
68. Vandewalle B., Revillion F., Lefebvre J. Functional beta-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol. 1990 ; 116: 303-306.
69. Marchetti B., Spinola PG, Pelletier G., Labrie F. A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of beta-adrenergic receptors and correlation with tumor growth. J Steroid Biochem Mol Biol. 1991 ; 38: 307-320.
70. Sheppard WD, Staggers F., Johns L. The effects of a stress management program in a high security government agency. Anxiety Stress Coping. 1997 ; 10: 341-350.
71. Clayborne B., Alexander C., Schneider R., et al. Effects of stress reduction on anger and cardiovascular reactivity in hypertensive African Americans: a randomized, controlled trial of Transcendental Meditation and progressive relaxation. Paper presented at: 12th International Conference on Hypertension in Blacks ; July 20-23, 1997 ; London, UK.
72. Jevning R., Wilson AF, Smith WR Adrenocortical activity during meditation. Horm Behav. 1978 ; 10: 54-60.
73. Levitsky DK, Walton KG, MacLean CRK, et al. Reversal of neuroendocrine effects of chronic stress by the Transcendental Meditation technique. Soc Neurosci Abstr. 1995 ; 21: 1389.
74. Goodwin PJ, Leszcz M., Ennis M., et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001 ; 345: 1719-1726.
75. Eschiti V. Lesson from comparison of CAM use by women with female-specific cancers to others: itĝ€™s time to focus on interaction risks with CAM therapies. Integr Cancer Ther. 2007 ; 6: 313-344.
76. Perry S., Kowalski TL, Chang CH Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes. 2007 ; 5: 24.
77. Knopf M. Psychosocial responses in breast cancer survivors. Semin Oncol Nurs. 2007 ; 23: 71-83.